Skip to main content

Table 1 Characteristics of the included randomized controlled trials and two incompletely reported trials

From: Efficacy of Ambroxol lozenges for pharyngitis: a meta-analysis

References Number of participants Age (yr) Setting (country) Treatment Comparison Follow up Dropouts
de Mey et al. 2008 [15] 92 n.r.* outpatients (n.r) Ambroxol 5, 10, 20 mg Placebo 1 day 11
Schutz et al. 2002,[14] 215 39,4 ± 15 outpatients (Germany) Ambroxol 20 mg Placebo 2 days 19
Fischer et al. 2002 [16] 331 37 ± 13 outpatients (RSA) Ambroxol 20, 30 mg Placebo 3 days 48
Fischer et al. 2002 [16] 383 36 ± 12 outpatients (RSA) Ambroxol 20, 30 mg Placebo 3 days 58
de Mey et al. 2008 [15] 751 n.r.* outpatients (n.r.) Ambroxol 20, 3 mg benzocaine** Placebo 3 days 27
Registered trials with incompletely reported results
clinicaltrials.gov 2006 221 n.r. outpatients (RSA) Ambroxol 20 mg Placebo 3 days 0
clinicaltrials.gov 2008 259 n.r. outpatients (China) Ambroxol 20 mg Placebo n.r. 0
  1. n.r. = not reported, RSA = Republic of South Africa, * inclusion age was 16 to 80 years, but average age for those trials was not reported **the outcome of the benzocaine treatment arm is not reported.